China Approves J&J's Oral Psoriasis Pill Icotrokinra
JNJ sits 58% above its 52-week low of $173.33.
Summary
China's approval of icotrokinra opens a major market for J&J's oral psoriasis treatment. The drug targets moderate-to-severe plaque psoriasis, a large patient population in China. This is a new regulatory milestone not previously reported in the timeline. The approval could drive incremental revenue and strengthen J&J's immunology franchise. Watch for launch timing and pricing details.
At the time of this announcement, JNJ was trading at $273.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $658.2B. The 52-week trading range was $173.33 to $276.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.